7 results about "High recurrence rate" patented technology

The gastroesophageal collar being submitted for patent intends to primarily prevent the ascension of the fundus above the diaphragmatic plane and also secondarily to improve the function of the Lower esophageal sphincter, thirdly to reduce occurrences of esophageal reflux and thereby hopefully reducing instances of esophageal cancer. It is estimated as high as %20 of the general population has a hiatal hernia experiencing symptoms of acid reflux and making them at higher risk for esophageal cancer. Currently the standard surgical repair of hiatus is fundoplication. The limitations of fundoplication are its high recurrence rate. It often requires a later second procedure to repair / tighten the fundoplication. By using supple bio-inert materials we intend to create a collar that can be left in place, mechanically preventing the ascension of the fundus and improving LES function. We hope to be the first Collar to prevent hiatal hernia and also improve LES function.

The present application relates to the field of biological medicine, and more particularly to the application of WDR5 inhibitors in the preparation of drugs for treating EBV-positive lymphoma. The WDR5 inhibitor is a small molecule inhibitor, including one or more of WDR5-specific degradation agent MS67, WDR5 WIN site-specific inhibitor OICR-9429, and WDR5 WBM site-specific inhibitor AA126. The present application first discovers that WDR5 is a key factor for regulating EBV reactivation in EBV-positive lymphoma cells, and provides the application of WDR5 inhibitors as active ingredients in the preparation of drugs for treating EBV-positive lymphoma, solving the clinical pain points of the lack of specific targets, large toxic and side effects, and high recurrence rate in the existing EBV-positive lymphoma treatment, and providing a new precise targeted treatment scheme for such diseases.

This invention discloses a traditional Chinese medicine composition for improving diarrhea, belonging to the field of traditional Chinese medicine technology. Addressing the shortcomings of existing antidiarrheal techniques, which only treat the symptoms and not the root cause, have significant side effects, high recurrence rates, and easily cause damage to the intestinal microcirculation, this invention is based on the original microscopic pathogenesis of small intestinal microvascular spasm and ischemia, and abnormal intestinal fluid metabolism. It is prepared by combining peppermint, angelica dahurica, nutmeg, cinnamon, platycodon grandiflorus, and angelica sinensis. The synergistic effect of each herb can target and relax spasmodic small intestinal microvessels, restore normal intestinal blood perfusion, regulate intestinal peristalsis rhythm, bidirectionally regulate intestinal fluid secretion and reabsorption, and simultaneously block abnormal stress signals in the brain-gut axis, repairing intestinal microcirculatory damage. This invention has a scientifically formulated composition, mild medicinal properties, and no side effects. It addresses the root causes of various acute, chronic, and functional diarrheas caused by cold stimulation, emotional stress, and spleen deficiency with cold stagnation, exhibiting strong curative effect and an extremely low recurrence rate, possessing high clinical promotion and application value.

The invention provides an eCRSwNP nasal endoscopic postoperative treatment method for regulating acidophilic granulocyte activity based on acupuncture, and relates to the technical field of traditional Chinese medicine for preventing and treating nasosinusitis diseases. According to the eCRSwNP nasal endoscopic post-operation treatment method for adjusting the acidophilic granulocyte activity based on acupuncture, accurate adjustment of the acidophilic granulocyte activity is achieved through a synergistic scheme of a nasal endoscopic operation, perioperative drug treatment and standardized acupuncture treatment, the postoperative recurrence rate is reduced, and the nasal symptom and life quality of a patient are improved. Acupuncture point selection, operation specifications, treatment frequency and treatment course of acupuncture are defined, a repeatable and generalizable standardized treatment scheme is formed in combination with strict patient screening standards, a quality control system and ethical guarantee, the technical problems that existing eCRSwNP postoperative treatment is lack of targeted immunoregulation means and the recurrence rate is high are solved, and the therapeutic effect of the eCRSwNP postoperative treatment is improved. And a new clinical path is provided for traditional Chinese medicine intervention on refractory nasosinusitis diseases.

The application provides an application of 3-(methylsulfonyl) propionitrile in preparation of a medicine for treating peripheral nerve adhesion diseases, relates to the field of biomedical technology, and is verified through a sciatic nerve adhesion mouse model that 3-(methylsulfonyl) propionitrile can effectively reduce the adhesion degree of nerves and peripheral tissues, and can significantly improve muscle atrophy symptoms; compared with the traumatic and high recurrence rate of surgical treatment, the drug is a non-invasive or minimally invasive treatment, has good patient tolerance, can effectively reduce treatment risks and rehabilitation costs, and has wider clinical applicability. Secondly, the drug plays a treatment effect through a double action mechanism: on the one hand, adhesion formation is inhibited, and nerve compression is released; on the other hand, nerve myelin sheath regeneration can be promoted, myelin sheath structure integrity is improved, nerve conduction velocity is improved, and the synergistic effect of 'adhesion release + nerve repair' is realized. Animal experiments prove that the drug can significantly improve the motion balance ability and gait function of model mice.

The application discloses a kind of pharmaceutical composition, preparation and preparation method of treating fibromyalgia syndrome, it is related to chronic pain disease treatment technical field.The pharmaceutical composition includes white flesh lucid ganoderma polysaccharide, quercetin, hesperetin and naringenin.The application further discloses a kind of pharmaceutical preparation for treating fibromyalgia syndrome and preparation method thereof.The pharmaceutical composition can effectively solve the problems of poor effect, high recurrence rate and obvious side effects of existing fibromyalgia syndrome treatment drugs;The application uses natural product to be matched, side effect is small, and can significantly improve the improvement effect on the core symptom of fibromyalgia syndrome.

The invention relates to the technical field of biological medicines, and provides application of a BCAA inhibitor in preparation of medicines for inhibiting, preventing, relieving or treating mutant leukemia aiming at the problems of high drug resistance, high recurrence rate and limited treatment effect in treatment of DNMT3A mutant AML patients at present. The BCAA inhibitor is gabapentin and / or cytarabine arabinoside. Experiments prove that gabapentin has a treatment effect on DNMT3A mutated acute myelogenous leukemia, meanwhile, it is found that DNMT3A mutated acute myelogenous leukemia cells have drug resistance to cytarabine, and the gabapentin and the cytarabine are combined to have a synergistic effect on the DNMT3A mutated acute myelogenous leukemia. The discovery of the application provides a new thought and direction for treatment of mutant leukemia, especially acute myelogenous leukemia with DNMT3A mutation.